ARF ietekme uz HCV core pamata izveidoto ģenētisko vakcīnu imunoloģiskām īpašībām
Funding: Latvian Council of Science
Project number: 532/2012
Project manager: Dr.biol.I.Sominska
The objective of this study consists in the elucidation of the molecular mechanisms behind HCV core immunogenic performance and its involvement into design of improved HCV core-based DNA immunogens, in order to develop them into “equal partners” or “first line players” compared to other HCV antigens.
The central aim of the study is the structural, functional, and immunological characterization of genetic vaccines on the basis of HCV core.
- Designing new and improving existing HCV core containing plasmids.
- Expression of HCV core containing plasmids in eukaryotic cells, in order to clarify the structural, immunological, and cytopathogenic properties.
- Immunization of mice.
- Detection of immune response.
- Selection of the most promising vaccine candidates.
Proposed ideas how to get effective antiviral vaccine prototype remain the most effective and safest way to combat viral diseases. Thanks to vaccination, the world has eliminated many dangerous infectious diseases. Effective vaccination significantly saves public funds spent on the treatment of patients. Work on the creation of an effective vaccine will increase our knowledge of infectious viruses and the immune system; promote modern biomedicine and biotechnology, Latvian and international cooperation and contacts with biotech companies.
The project is highly interdisciplinary by the character, as it relates to molecular biology, virology, and medicine. The project is expected to demonstrate direct impact on such Latvia's traditional economic and applied science branches as biomedicine and pharmacy. Taking into account the long-term cooperation between BMC and Grindex, LOSI, RTU, RSU, it is possible.